Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus XULANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus XULANE.
ASHLYNA vs XULANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Ethinyl estradiol and norelgestromin (the active metabolites of norgestimate) suppress gonadotropin release, inhibiting ovulation and increasing cervical mucus viscosity, impairing sperm penetration.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
Apply 1 patch (20 cm² containing 600 mcg ethinyl estradiol and 6 mg norelgestromin) transdermally once weekly for 3 weeks, followed by 1 patch-free week.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life is 4.5 hours; in severe renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 12-15 hours, requiring dose adjustment.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Primarily renal (approximately 60-70% as unchanged drug), with biliary/fecal elimination accounting for 20-30%.
Category C
Category C
Contraceptive
Contraceptive